Cargando…

Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer

BACKGROUND: Patients with locally advanced and high-risk prostate cancer (LAPC) are prone to experience biochemical recurrence despite radical prostatectomy (RP). We evaluated feasibility, safety and activity of a neoadjuvant chemohormonal therapy (NCHT) with 3-weekly full dose docetaxel and complet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thalgott, Mark, Horn, Thomas, Heck, Matthias M, Maurer, Tobias, Eiber, Matthias, Retz, Margitta, Autenrieth, Michael, Herkommer, Kathleen, Krause, Bernd J, Gschwend, Jürgen E, Treiber, Uwe, Kübler, Hubert R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3974001/ https://www.ncbi.nlm.nih.gov/pubmed/24598155 http://dx.doi.org/10.1186/1756-8722-7-20

Ejemplares similares

Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients
por: Thalgott, Mark, et al.
Publicado: (2015)

[(11)C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy
por: Schwarzenböck, Sarah M., et al.
Publicado: (2016)

KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy
por: Lunger, Lukas, et al.
Publicado: (2020)

Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients
por: Heck, Matthias M., et al.
Publicado: (2013)

Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer
por: Babst, Christa, et al.
Publicado: (2022)

Current Staging Procedures in Urinary Bladder Cancer
por: Maurer, Tobias, et al.
Publicado: (2013)

Human papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational study
por: Schmid, Sebastian C., et al.
Publicado: (2015)

Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer
por: Mellado, B, et al.
Publicado: (2009)

Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy
por: Sathe, A, et al.
Publicado: (2014)

Both radiographical and pathological lymph node statuses are independent predictors for survival following neoadjuvant chemotherapy and radical cystectomy for cT3/4 or cN+ bladder cancer
por: Wagner, Julia, et al.
Publicado: (2022)

S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer
por: Nawroth, Roman, et al.
Publicado: (2011)

Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer
por: Lunger, Lukas, et al.
Publicado: (2021)

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
por: Lückerath, Katharina, et al.
Publicado: (2018)

The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma
por: Erlmeier, F., et al.
Publicado: (2016)

Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer – study protocol of a prospective, single arm, multicenter phase II trial (RACE IT)
por: Schmid, Sebastian C., et al.
Publicado: (2020)

Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)
por: Habl, Gregor, et al.
Publicado: (2017)

Ultrasound-based “CEUS-Bosniak”classification for cystic renal lesions: an 8-year clinical experience
por: Herms, Elena, et al.
Publicado: (2022)

Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer
por: Narita, Shintaro, et al.
Publicado: (2012)

PSMA-targeted imaging of prostate cancer: evolution of a success story
por: Maurer, Tobias, et al.
Publicado: (2017)

The value of (68)Ga-PSMA enhanced PET-CT and MR-PET in patients with biochemical recurrent prostate cancer
por: Rummeny, E, et al.
Publicado: (2015)

Changing nationwide trends away from overtreatment among patients undergoing radical prostatectomy over the past 25 years
por: Meissner, Valentin H., et al.
Publicado: (2023)

Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study
por: Dewes, Sabrina, et al.
Publicado: (2016)

A CT-based radiomics model to detect prostate cancer lymph node metastases in PSMA radioguided surgery patients
por: Peeken, Jan C., et al.
Publicado: (2020)

Multimodal therapy in oligometastatic prostate cancer: A glimpse into the future?
por: Knipper, Sophie, et al.
Publicado: (2021)

Benefit finding in long-term prostate cancer survivors
por: Lassmann, Irène, et al.
Publicado: (2021)

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
por: Lin, Binwei, et al.
Publicado: (2023)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
por: Li, Jian-Ri, et al.
Publicado: (2017)

Erratum zu: Selbstuntersuchung von Hoden und Brust – eine retrospektive Kohortenstudie an Medizinstudierenden
por: Jahnen, Matthias, et al.
Publicado: (2021)

Selbstuntersuchung von Hoden und Brust – eine retrospektive Kohortenstudie an Medizinstudierenden
por: Jahnen, Matthias, et al.
Publicado: (2021)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Stellenwert der Immuntherapie in der perioperativen Behandlung des lokalisierten muskelinvasiven Harnblasenkarzinoms
por: Lewerich, J., et al.
Publicado: (2022)

Maximal androgen blockade for advanced prostate cancer
por: Mukha, Rajiv Paul, et al.
Publicado: (2010)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Benefit finding in men affected by prostate cancer prior to and following radical prostatectomy – a cross-sectional study with a stratified sample
por: Jahnen, Matthias, et al.
Publicado: (2023)

Impact of (68)Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology - a patterns of failure analysis in patients with primary diagnosis of prostate cancer
por: Schiller, K., et al.
Publicado: (2018)

Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials
por: Zhuang, Junlong, et al.
Publicado: (2023)

The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review
por: Chen, Long, et al.
Publicado: (2014)

Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model
por: Mirjolet, Céline, et al.
Publicado: (2017)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
por: Li, Qi, et al.
Publicado: (2019)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s66mgtjca0basoafm8m8gcca03